Research programme: kallikrein inhibitors - ActiveSite Pharmaceuticals

Drug Profile

Research programme: kallikrein inhibitors - ActiveSite Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ActiveSite Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetic macular oedema; Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in USA (PO)
  • 07 May 2012 ActiveSite Pharmaceuticals receives Phase II SBIR grant from NIH's National Eye Institute for kallikrein inhibitor development in Diabetic macular oedema
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top